Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 glomerulopathy or primary immune-complex MPGN. (Funded by Apellis Pharmaceuticals and Sobi Swedish Orphan Biovitrum; VALIANT ClinicalTrials.gov number, NCT05067127.).
Ariceta et al. (Wed,) studied this question.